RAPIBLOC
300MG INF PLV SOL 1
| SÚKL code | 0214231 |
|---|---|
| Name of the product | RAPIBLOC |
| _MA_MEDICATION_DETAIL_INFO_MED_NAME i | RAPIBLOC |
| Supplement | 300MG INF PLV SOL 1 |
| Strenght | 300MG |
| Pharmaceutical form | Powder for solution for infusion |
| Package | 1 |
| Route | Intravenous use |
| Language of the pack | Czech |
| Wrap type | Vial |
| Legal status | na lékařský předpis |
| Active substance | LANDIOLOL HYDROCHLORIDE (LANDIOLOLI HYDROCHLORIDI) |
| ATC group | C07AB14 |
| ATC group name | LANDIOLOL |
| Doping | Diuretika a ostatní maskovací látky (nelze pro léčbu sportovců použít vůbec). Bližší informace viz http://www.antidoping.cz/. |
Marketing authorisation information
| Registration Number | 58/ 487/14-C |
|---|---|
| Type of MA | A mutual recognition procedure (MRP, DCP), where CZ is Concerned member state |
| MA status | B - medicinal product after change, may be placed on the market for the period of 6 months (Placed on the market till) and used until expiration, not later than till the end of validity of the marketing authorisation (Valid till) |
| Placed on the market till | 30. 04. 2018 |
| MA Holder | AOP Orphan Pharmaceuticals AG, Wien |
| MA Holder country | RAKOUSKO |
| Actual MA holder | Amomed Pharma GmbH, Vídeň |
| Actual MA holder country | RAKOUSKO |
cz